Onasemnogene abeparvovec (ZOLGENSMA intrathecal) 1 patient set

Open tender

Japanese title: オナセムノゲンアベパルボベク(販売名:ゾルゲンスマ髄注)1患者当たり1式

Medical
About this page
This page is based on the official tender notice and presents information processed, translated, and edited by JBID.

Overview

This tender is for the procurement of Onasemnogene abeparvovec (ZOLGENSMA suspension for intrathecal injection), one set per patient, to be delivered to Saga University Hospital between September 3, 2026 and March 31, 2027. Participation requires pharmaceutical sales authorization and compliance with Saga University procurement regulations.

Key Details

  • Source: Kanpo
  • Notice type: Open tender
  • Publication date: July 13, 2026
  • Procuring entity: Koichi NODE, President, National University Corporation Saga University
  • Submission deadline: September 2, 2026, 12:00 JST
  • Bid opening: September 3, 2026, 11:00 JST, location: see the official notice
  • Award method: Lowest-price award
  • Eligibility (from notice): All-ministry unified qualification, 'goods sales', grade A–C, Kyushu-Okinawa region – verify in the tender documents
  • Status: Expired
  • Technology relevance: Possible
  • Business-action likelihood: Medium – The procurement is specialized pharmaceutical supply requiring specific licensing and regional qualification, suggesting moderate barriers and need for compliance with local regulations.

Official Notice

Official Source

Kanpo, Japan's official government gazette, in which legally required public procurement notices are formally published.

  • Source: Kanpo, Government Procurement Notice Edition
  • Official category: 入札公告 / Open competitive tender notice
  • Publication date: July 13, 2026
  • Publication: Kanpo, pages 65

Full English Translation

The following English translation was prepared from the original Japanese notice published in Kanpo. Where an official English summary appears in the Kanpo publication, it was used only for verification; the translation below is based on the Japanese source text.

Tender notice:
The following is subject to open competitive bidding. July 13, 2026, National University Corporation Saga University, President Koichi NODE. Procurement agency number 415, location number 41. Item classification number 4. Procurement subject and quantity: Onasemnogene abeparvovec (trade name: ZOLGENSMA suspension for intrathecal injection), one set per patient. Delivery deadline: From September 3, 2026 to March 31, 2027. Delivery location: Saga University Hospital, Faculty of Medicine. Tender method: The winning bid price will be the bid amount plus 10% of that amount (fractions less than 1 yen are rounded down). Bidders must enter 100/110 of the estimated contract amount on the bid form regardless of tax status. Eligibility: Bidders must not fall under Articles 3 and 4 of Saga University procurement regulations. Minors or persons under guardianship with necessary consent may be eligible under special reasons. Bidders must be rated A, B, or C in the Kyushu-Okinawa region for 'sale of goods' in the national or Saga University procurement qualification for fiscal year 2026. Bidders must prove they hold a general pharmaceutical sales license under the Pharmaceutical and Medical Device Act. Bidders must have qualifications set by the university president and not be under transaction suspension. Bid submission location and contact: Management and Control Division, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga City 849-8501, Japan. Contact: KUBOI Ryou, phone 0952-34-3114, email [email protected]. Bid documents available from the date of this notice at the above location. Bid receipt deadline: September 2, 2026, 12:00. Bid opening: September 3, 2026, 11:00, Saga University Faculty of Medicine meeting room. Language and currency: Japanese and Japanese yen. No bid or contract guarantee required. Bidders must submit sealed bids with documents proving ability to supply the goods by the deadline. The university president will select the lowest valid bid within the price limit who can supply the goods. If the lowest bidder is deemed unable to fulfill the contract or would disrupt fair trade, the next lowest bidder will be selected. No negotiation in the procedure. Other details per bid documents. If environmental conditions are specified in the bid documents, bidders must understand them before bidding.
Show original Japanese notice

The full Japanese notice text is temporarily hidden on this page due to a text-extraction defect. The official notice is available via the Kanpo source link on this page.

Business Signal

Business Relevance

May interest companies providing advanced pharmaceutical gene therapy products or specialized medical supply services.

Participation fit

Participation is expected to require appropriate Japanese government procurement eligibility, or cooperation with a suitable Japanese partner holding the required qualification. The eligibility requirements have not been fully reviewed and should be verified against the official tender documents.

This page is based on the official Kanpo tender notice, with translation and a preliminary business assessment by I.J. Do. The official Japanese notice and tender documents are binding.

JBid is a beta technology-procurement intelligence service by I.J. Do.

Back to daily list